Silicone Oil Microdroplets Can Induce Antibody Responses Against Recombinant Murine Growth Hormone in Mice

被引:31
作者
Chisholm, Carly Fleagle [1 ]
Baker, Abby E. [1 ]
Soucie, Kaitlin R. [1 ]
Torres, Raul M. [2 ]
Carpenter, John F. [3 ]
Randolph, Theodore W. [1 ]
机构
[1] Univ Colorado, Dept Chem & Biol Engn, Boulder, CO 80309 USA
[2] Univ Colorado, Sch Med, Dept Immunol & Microbiol, Aurora, CO 80045 USA
[3] Univ Colorado, Dept Pharmaceut Sci, Anschutz Med Campus, Aurora, CO 80045 USA
关键词
protein formulation; protein structure; immune response; immunogenicity; protein aggregation; subvisible particles; particle size; prefilled syringes; silicone oil; adjuvant effect; HUMAN INTERFERON-BETA; MONOCLONAL-ANTIBODY; PARTICLE FORMATION; PROTEIN AGGREGATION; WATER INTERFACES; IMMUNE-RESPONSE; GAMMA-GLOBULIN; IMMUNOGENICITY; GLASS; FORMULATIONS;
D O I
10.1016/j.xphs.2016.02.019
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Therapeutic protein products can cause adverse immune responses in patients. The presence of sub-visible particles is a potential contributing factor to the immunogenicity of parenterally administered therapeutic protein formulations. Silicone oil microdroplets, which derive from silicone oil used as a lubricating coating on barrels of prefilled glass syringes, are often found in formulations. In this study, we investigated the potential of silicone oil microdroplets to act as adjuvants to induce an immune response in mice against a recombinant murine protein. Antibody responses in mice to subcutaneous injections of formulations of recombinant murine growth hormone (rmGH) that contained silicone oil microdroplets were measured and compared to responses to oil-free rmGH formulations. When rmGH formulations containing silicone oil microdroplets were administered once every other week, anti-rmGH antibodies were not detected. In contrast, mice exhibited a small IgG1 response against rmGH when silicone oil-e containing rmGH formulations were administered daily, and an anti-rmGH IgM response was observed at later time points. Our findings showed that silicone oil microdroplets can act as an adjuvant to promote a break in immunological tolerance and induce antibody responses against a recombinant self-protein. (C) 2016 American Pharmacists Association (R). Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:1623 / 1632
页数:10
相关论文
共 69 条
  • [51] An acid dissociation bridging ELISA for detection of antibodies directed against therapeutic proteins in the presence of antigen
    Patton, A
    Mullenix, MC
    Swanson, SJ
    Koren, E
    [J]. JOURNAL OF IMMUNOLOGICAL METHODS, 2005, 304 (1-2) : 189 - 195
  • [52] Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis
    Radstake, T. R. D. J.
    Svenson, M.
    Eijsbouts, A. M.
    van den Hoogen, F. H. J.
    Enevold, C.
    van Riel, P. L. C. M.
    Bendtzen, K.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2009, 68 (11) : 1739 - 1745
  • [53] Ring J, 1977, Monogr Allergy, V12, P27
  • [54] Romacker M., 2008, ONDRUGDELIVERY, P4
  • [55] Aggregation of Human Recombinant Monoclonal Antibodies Influences the Capacity of Dendritic Cells to Stimulate Adaptive T-Cell Responses In Vitro
    Rombach-Riegraf, Verena
    Karle, Anette C.
    Wolf, Babette
    Sorde, Laetitia
    Koepke, Stephan
    Gottlieb, Sascha
    Krieg, Jennifer
    Djidja, Marie-Claude
    Baban, Aida
    Spindeldreher, Sebastian
    Koulov, Atanas V.
    Kiessling, Andrea
    [J]. PLOS ONE, 2014, 9 (01):
  • [56] Effects of protein aggregates: An immunologic perspective
    Rosenberg, Amy S.
    [J]. AAPS JOURNAL, 2006, 8 (03) : E501 - E507
  • [57] Ross C, 2000, ANN NEUROL, V48, P706, DOI 10.1002/1531-8249(200011)48:5<706::AID-ANA3>3.0.CO
  • [58] 2-V
  • [59] Immunological mechanism underlying the immune response to recombinant human protein therapeutics
    Sauerborn, Melody
    Brinks, Vera
    Jiskoot, Wim
    Schellekens, Huub
    [J]. TRENDS IN PHARMACOLOGICAL SCIENCES, 2010, 31 (02) : 53 - 59
  • [60] Immunogenicity of therapeutic proteins: Clinical implications and future prospects
    Schellekens, H
    [J]. CLINICAL THERAPEUTICS, 2002, 24 (11) : 1720 - 1740